LIXT vs. CARA, COCP, TENX, XCUR, ATHA, GOVX, MIRA, BTAI, CYTH, and APRE
Should you be buying Lixte Biotechnology stock or one of its competitors? The main competitors of Lixte Biotechnology include Cara Therapeutics (CARA), Cocrystal Pharma (COCP), Tenax Therapeutics (TENX), Exicure (XCUR), Athira Pharma (ATHA), GeoVax Labs (GOVX), MIRA Pharmaceuticals (MIRA), BioXcel Therapeutics (BTAI), Cyclo Therapeutics (CYTH), and Aprea Therapeutics (APRE). These companies are all part of the "pharmaceutical products" industry.
Lixte Biotechnology vs.
Lixte Biotechnology (NASDAQ:LIXT) and Cara Therapeutics (NASDAQ:CARA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, community ranking, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.
Lixte Biotechnology has a net margin of 0.00% compared to Cara Therapeutics' net margin of -1,099.76%. Cara Therapeutics' return on equity of -367.97% beat Lixte Biotechnology's return on equity.
Lixte Biotechnology has higher earnings, but lower revenue than Cara Therapeutics. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Cara Therapeutics, indicating that it is currently the more affordable of the two stocks.
Lixte Biotechnology has a beta of -0.08, suggesting that its share price is 108% less volatile than the S&P 500. Comparatively, Cara Therapeutics has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500.
Cara Therapeutics received 667 more outperform votes than Lixte Biotechnology when rated by MarketBeat users.
Cara Therapeutics has a consensus target price of $27.84, suggesting a potential upside of 489.21%. Given Cara Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cara Therapeutics is more favorable than Lixte Biotechnology.
In the previous week, Cara Therapeutics had 1 more articles in the media than Lixte Biotechnology. MarketBeat recorded 1 mentions for Cara Therapeutics and 0 mentions for Lixte Biotechnology. Cara Therapeutics' average media sentiment score of 0.50 beat Lixte Biotechnology's score of 0.00 indicating that Cara Therapeutics is being referred to more favorably in the news media.
5.1% of Lixte Biotechnology shares are held by institutional investors. Comparatively, 44.7% of Cara Therapeutics shares are held by institutional investors. 14.8% of Lixte Biotechnology shares are held by company insiders. Comparatively, 3.1% of Cara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Cara Therapeutics beats Lixte Biotechnology on 11 of the 15 factors compared between the two stocks.
Get Lixte Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for LIXT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lixte Biotechnology Competitors List
Related Companies and Tools
This page (NASDAQ:LIXT) was last updated on 1/21/2025 by MarketBeat.com Staff
